Gayathri Kallukaran is a Junior Journalist with Eastern Eye. She has a Master’s degree in Journalism and Mass Communication from St. Paul’s College, Bengaluru, and brings over five years of experience in content creation, including two years in digital journalism. She covers stories across culture, lifestyle, travel, health, and technology, with a creative yet fact-driven approach to reporting. Known for her sensitivity towards human interest narratives, Gayathri’s storytelling often aims to inform, inspire, and empower. Her journey began as a layout designer and reporter for her college’s daily newsletter, where she also contributed short films and editorial features. Since then, she has worked with platforms like FWD Media, Pepper Content, and Petrons.com, where several of her interviews and features have gained spotlight recognition. Fluent in English, Malayalam, Tamil, and Hindi, she writes in English and Malayalam, continuing to explore inclusive, people-focused storytelling in the digital space.
Leaks surrounding the upcoming Google Pixel 10 have started surfacing, offering a first look at the tech giant’s next flagship device. Spotted on a public beach in Vancouver, Canada, the phone was reportedly being filmed for a TV advert, giving passers-by an unexpected preview. From design changes to new features and colour options, here are seven key things we’ve learnt from the leak.
1. Pixel 10 caught on camera during filming The Pixel 10 Pro (or possibly the Pixel 10 Pro XL) was seen in public during what appeared to be a promotional shoot for Google. A video production crew was spotted working on a beach, where a bystander was able to view the phone and even the storyboard for the shoot — a rare, unguarded glimpse into Google’s plans.
— (@)
2. New AI-powered camera feature: ‘Google Add Me’ The storyboard revealed an upcoming feature called Google Add Me, an AI tool designed to enhance group photography. The feature will allow users to add people to the same photo after it’s taken, such as including the photographer in the final image. This builds on Google's continued use of AI in the Pixel’s camera software.
3. Refined camera design continues The Pixel 10 appears to maintain the camera design introduced in previous models, a horizontal camera bar with a black oval housing the sensors. However, the leaked phone shows a slightly larger protruding oval with additional space, presumably for the LED flash, suggesting some refinement in the hardware layout.
4. Colour options revealed New colour variants were also uncovered in the leak. The Pixel 10 will reportedly come in:
Obsidian (Black)
Blue
Iris (Purple)
Limoncello (likely Yellow)
Meanwhile, the Pixel 10 Pro and Pro XL models are expected in:
Obsidian
Green
Sterling (Grey)
Porcelain (White)
5. Blue model spotted in the wild The device seen on the Vancouver beach appeared to be the Blue version of the Pixel 10, indicating Google will lean into bolder colours this time around. This adds visual variety compared to the typically muted palette of previous Pixel phones.
6. Possible multiple Pro models The leak mentions both Pixel 10 Pro and Pixel 10 Pro XL, suggesting Google may release two larger flagship models. If true, this would mark a return to the XL naming convention, which had been previously dropped in favour of the regular and Pro distinction.
7. Expected launch in August While the Pixel line traditionally launched in October, Google moved up the release of the Pixel 9 series to mid-August 2024. Based on the filming timeline and consistent patterns, it’s likely the Pixel 10 series will also launch around August 2025, maintaining this revised schedule.
With a mix of AI-powered features, new colours, and potential model variants, the Pixel 10 is shaping up to be one of Google’s most anticipated releases. The official launch is expected within the next few months.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.